首页> 外文期刊>European journal of ophthalmology >Cataract formation: A possible complication of intra-arterial chemotherapy for retinoblastoma
【24h】

Cataract formation: A possible complication of intra-arterial chemotherapy for retinoblastoma

机译:白内障形成:视网膜母细胞瘤的动脉内化疗的可能并发症

获取原文
获取原文并翻译 | 示例
       

摘要

Purpose: To delineate and discuss a not yet described possible ocular complication of selective intraarterial chemotherapy (SIAC) for treatment of retinoblastoma. Methods: A 23-month-old girl with a large unilateral retinoblastoma was treated with repeated SIAC using 5 mg melphalan between July 2010 and January 2012. Clinical course of tumor and further ocular changes after therapy and histopathologic findings are described. Results: In total, 5 SIAC were performed over a time period of 18 months. After the last SIAC, diffuse dense cataract prevented further funduscopy. In addition, anterior chamber seeding was obvious, leading to the decision to enucleate the eye. Histopathologically, nearly complete regression of the main tumor mass with prominent calcifications, but vital tumor seeding in the vitreous, on the lens surface, on the ciliary body, and in the anterior chamber, was observed. Peculiar vacuolation of the lens epithelial cells, liquefaction of the subepithelial lens fibers, and diffuse small vacuoles within the lens were striking. Conclusions: Repeated SIAC with melphalan may induce cataract formation, possibly as a toxic effect of the chemotherapeutic to the lens, maybe combined with radiation exposure during fluoroscopy. This ocular complication should be taken into consideration as a limitation of the number of feasible repeated treatments.
机译:目的:描述和讨论选择性视网膜内动脉化疗(SIAC)治疗视网膜母细胞瘤的尚未发生的眼部并发症。方法:从2010年7月至2012年1月,对5月龄的23个月大单侧视网膜母细胞瘤女孩进行反复SIAC治疗,使用5 mg美法仑。描述了肿瘤的临床病程以及治疗后进一步的眼部改变和组织病理学发现。结果:在18个月的时间内总共进行了5次SIAC。上次SIAC后,弥漫性密集性白内障阻止了进一步的眼底检查。此外,前房播种明显,导致决定摘除眼球。在组织病理学上,观察到主要肿瘤块几乎完全消退,并伴有明显钙化,但在玻璃体,晶状体表面,睫状体和前房中观察到重要的肿瘤播种。晶状体上皮细胞奇异的空泡化,上皮下晶状体纤维的液化和晶状体内弥散的小液泡引人注目。结论:反复使用美法仑的SIAC可能诱发白内障形成,可能是化学疗法对晶状体的毒性作用,也可能与荧光检查时的放射线照射相结合。这种眼部并发症应考虑为可行的重复治疗次数的限制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号